Capecitabine utilizes a three-step enzymatic conversion process, concluding with the enzyme thymidine phosphorylase, which is naturally more concentrated inside cancerous tumors than healthy tissue.

It is a cutaneous toxicity causing redness, swelling, tingling, and peeling on the palms and soles. It is managed with heavy moisturizers, avoiding friction, and adjusting the drug dose if necessary.

It must be swallowed with water within 30 minutes after completing a meal (breakfast or dinner) to ensure proper rate of absorption.

Capecitabine-induced enterotoxicity can cause rapid, severe dehydration and electrolyte imbalances. Diarrhea matching or exceeding 4 episodes a day requires immediate medical attention.

Yes, it can cause a significant increase in anticoagulant effects, leading to bleeding risks. Prothrombin time and INR must be monitored very closely.

No. Patients with a dihydropyrimidine dehydrogenase (DPD) deficiency cannot properly metabolize fluorouracil, which can lead to life-threatening toxicity.

Unlike traditional intravenous chemotherapies, Capecitabine causes only minimal hair thinning or mild alopecia in a small percentage of patients.

There are no strict exclusions, but maintaining proper hydration (8-10 glasses of water daily) is essential to protect renal function.

It damages human oocytes and spermatozoa. Both partners must use reliable contraception during therapy and for at least 6 months following the final dose.

A standard cycle usually involves 14 days of twice-daily oral dosing followed by a 7-day rest period, repeated every 3 weeks.